FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results
February 26, 2024 16:06 ET
|
FibroGen, Inc.
• Topline data from two pivotal pamrevlumab pancreatic cancer trials anticipated in 2Q 2024 • Additional data from Phase 1 monotherapy study of FG-3246 in metastatic castration-resistant prostate...
FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results
February 20, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce fourth quarter and full year 2023 financial results on Monday, February 26 after the market close....
FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024
February 05, 2024 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced it will host Part I of a virtual KOL investor event series on Tuesday, February 13, 2024 at 10:30 AM...
FibroGen Reports Second Quarter 2023 Financial Results
August 07, 2023 16:01 ET
|
FibroGen, Inc.
Topline data from three late-stage pamrevlumab trials expected through 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in metastatic pancreatic...
FibroGen Reports First Quarter 2023 Financial Results
May 08, 2023 16:01 ET
|
FibroGen, Inc.
• Topline Data From Four Phase 3 Trials Expected Through 3Q 2023 • Completed Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value • Entered Into...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 03, 2023 07:00 ET
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
FibroGen Reports Third Quarter 2022 Financial Results
November 07, 2022 16:01 ET
|
FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
FibroGen to Participate at Stifel 2022 Healthcare Conference
November 01, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 01, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Stifel 2022...
FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
June 08, 2022 07:00 ET
|
FibroGen, Inc.
- 73 Ambulatory DMD Patients Enrolled -- Topline Data Anticipated 2H:2023 - SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced completion of patient...
FibroGen to Present at Jefferies Healthcare Conference
May 26, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, May 26, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies...